🟢 Health ETF (ARKG) is trading 3.1% up as Lilly’s obesity-drug results may contribute

ARKG is trading at $55.66, up 3.08%, with Eli Lilly’s obesity-drug results potentially contributing to optimism.

• Lilly’s EloraTZP Phase 2b results showed up to 23.3% average weight loss, supporting optimism about obesity-drug innovation.
• Lilly is 3.40% of ARKG, so its news alone does not establish the fund-wide move.
• Broader indexes are mixed-to-positive, with no clear healthcare-wide catalyst; the exact driver of ARKG’s larger gain is uncertain.